Let us look at some biotech stocks, AMGN, CRSP, MRNA, SRPT and VRTX, which are poised to beat on fourth-quarter earnings.

Let's look at five pharma and drug companies, MRK PFE, LLY, AMGN and BMY, which are scheduled to release their fourth-quarter ...

Cathie Wood and Ark Invest sold roughly $7,379,804 worth of Palantir stock — and spent $9,145,824 on three biotech stocks.

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

making it an attractive value play if the company can generate the earnings expected. The stock is trading near the lowest level it has seen since 2021. Our curated list of the best biotechnology ...

Oncolytics Biotech Inc. (ONCY) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

As the U.S. stock market navigates through a week of fluctuating tech earnings and pivotal economic data, investors are keenly observing how these developments influence broader indices like the ...

Shares of Amgen (AMGN) fell in after-hours trading after the biotechnology company reported earnings for its fourth quarter ...

Amgen reported strong fourth-quarter earnings, driven by strategic acquisitions and robust product sales growth.

Vertex Pharmaceuticals ( VRTX 2.53%) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs ...

Analysts at HC Wainwright increased their FY2024 earnings per share estimates for shares of Evaxion Biotech A/S in a note issued to investors on Monday, February 3rd. HC Wainwright analyst S.